+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effects of vericiguat compared to placebo in children and adolescents with heart failure caused by left ventricular systolic dysfunction. The study aims to determine if vericiguat can better reduce levels of a heart failure marker called NT-proBNP over 16 weeks. This research is a Phase 23 clinical trial assessing efficacy, safety, and pharmacokinetics in pediatric participants. Participants receive either vericiguat or placebo daily by mouth in tablet or suspension form for 52 weeks during the Base Period. After completing this phase, eligible participants can join an optional open-label Extension Period where they receive vericiguat daily. The study incorporates a previously separate extension arm, allowing long-term follow-up of up to approximately 8 years. Throughout the study, participants will have their NT-proBNP levels measured and monitored at various time points, including baseline, Week 16, Week 52, and during the Extension Period. Researchers will also track adverse events and reasons for stopping the study drug. Additional assessments include heart failure events, pharmacokinetic measurements, and safety evaluations. The total study duration can extend up to 8 years for some participants.

Age: 29Days - 17YearsAll GendersPhase 2Phase 3
111 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying adults with stage 5 chronic kidney disease who are undergoing maintenance hemodialysis. The trial aims to evaluate how creatine monohydrate supplementation and a supervised exercise program during dialysis affect body composition, biochemical markers, and physical function. This double-blind, randomized clinical trial compares the separate and combined impacts of these interventions over an 8-week period. Participants will be assigned to one of four groups standard hemodialysis care, creatine supplementation, intradialytic exercise, or a combination of creatine and exercise. Creatine or placebo is given daily, with dosing times adjusted on dialysis and non-dialysis days. The exercise program includes aerobic and resistance activities performed three times weekly during dialysis sessions. The intervention lasts for 8 weeks. Throughout the study, participants will have assessments of muscle strength, body composition, and biochemical parameters at baseline and after the intervention. Researchers will measure grasping muscle strength as the primary outcome. The trial includes safety monitoring for adverse events related to creatine use. Participation spans the 8-week intervention period with regular exercise and supplement administration alongside routine dialysis care.

Age: 18Years +All GendersPhase 1Phase 2
1 location